A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > ORGANIZATION
ORGANIZATION
- Generic Drug Share Reaches 23.6% in 3rd Quarter of FY2011: JGA
March 2, 2012
- EFPIA Japan Chairman Fauchet Says New Committee to Review Health Economic Assessment
March 1, 2012
- Daiichi-Sankyo, Eisai, Pfizer Japan Leaving Strongest Impression at Dispensing Pharmacies: NPhA Survey
February 29, 2012
- JPWA President Bessho Welcomes NPhA’s Efforts for Drug Distribution Improvement
February 29, 2012
- JPA Incumbent President Kodama Reelected as Next Term Candidate
February 28, 2012
- Sales by Member Companies Rose 5% in 2011: JCROA
February 28, 2012
- NPhA Refers Plan to Recommend Next President to Board Review
February 27, 2012
- Toshiki Iwasaki to Step Down as NPhA President in May
February 24, 2012
- JSCTR to Set Up“GCP Expert” Certification to Improve Quality of Clinical Studies
February 21, 2012
- Japan Pharmaceutical Political Association Chairman Kumakura to Focus on Resolving Price Difference
February 21, 2012
- Prof. Kimura of Saga Univ. Receives Top Award for Research on Ubiquilin 1 Inhibitor
February 17, 2012
- 12 Organizations from 11 Countries, Regions to Participate in Asian Cooperation Conference
February 16, 2012
- JPMA VP Nogimori Focused on Thorough Compliance, Promotion of International Cooperation
February 15, 2012
- KIF5B-RET Fusion Gene Identified as Potential Target in Pulmonary Adenocarcinoma
February 13, 2012
- NPhA Compiles Draft Proposal for Mutual Understanding to Improve Distribution
February 10, 2012
- MHLW “Missing the Bigger Picture” in Measures to Eliminate Drug Lag: Prof. Nakamura
February 10, 2012
- PhRMA Concerned that Health Economic Evaluation Will Be Used to Reduce NHI Prices: Mr Zulueta
February 6, 2012
- JACDS to Strengthen Support to Ensure Compliance in Sale of OTC Drugs
February 6, 2012
- It Is Difficult to Check Off-Label Use of Generics Approved for Indications Different from Those of Original Drugs: Medical Bill Payment Fund
February 1, 2012
- JPMA to Make Proposals on Pricing of Long-Listed Drugs to CSIMC: President Teshirogi
January 31, 2012
ページ
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…